Clinical disease activity and systemic inflammation are independent predictors of mortality from cardiovascular disease (CVD) in rheumatoid arthritis (RA) [1], and studies have shown that methotrexate and tumour necrosis factor-α inhibitors (TNF-α) therapy can reduce CVD mortality [2]. Here, TNF is linked to rheumatoid arthritis.